Anti-FcεRIα Autoantibodies in Autoimmune-mediated Disorders
Identification of a Structure–Function Relationship

Edda Fiebiger,* Franz Hammerschmid,† Georg Stingl,* and Dieter Maurer*
*Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases (DIAID), University of Vienna Medical School, A-1090 Vienna, Austria; and †Novartis Research Institute, A-1235 Vienna, Austria

Abstract

Anti-FcεRIα autoantibodies (autoAbs) occur and may be of pathogenetic relevance in a subset of chronic urticaria (CU) patients. To analyze the prevalence and magnitude of the humoral anti-FcεRIα response in cohorts of CU patients compared with individuals suffering from classic skin-related (auto)immune diseases, we developed an ELISA system for the measurement of anti-FcεRIα autoAbs in non-fractionated serum samples. Results obtained using this assay correlated well with those generated by Western blotting. We found IgG anti-FcεRIα autoreactivity in 38% of CU patients but not in atopic dermatitis patients, psoriatics, or healthy individuals. We frequently detected anti-FcεRIα autoAbs in pemphigus vulgaris (PV, 39%), dermatomyositis (DM, 36%), systemic lupus erythematosus (SLE, 20%), and bullous pemphigoid (BP, 13%). While the autoAb titers in DM, SLE, BP, and PV were similar to those encountered in CU patients, only anti-FcεRIα + CU serum specimens displayed pronounced histamine-releasing activity. The anti-FcεRIα autoAbs in CU patients belong predominantly to the complement-fixing subtypes IgG1 and IgG3, whereas in DM, PV, and BP, they were found to be mainly of the IgG2 or IgG4 subtype. Complement-activating properties of anti-FcεRIα autoAbs can indeed be of pathogenetic relevance, because C5a receptor blockade on basophils as well as de-complementation reduced drastically the histamine-releasing capacity of most anti-FcεRIα-reactive CU sera. As a consequence, therapeutic efforts in CU should aim at altering not only the quantity but also the complement-activating properties of IgG anti-FcεRIα autoAbs. (J. Clin. Invest. 1998, 101:243–251.) Key words: autoimmuneity · IgE receptors · histamine release · complement activation · chronic urticaria

Introduction

Chronic urticaria (CU)1 is a distressing affliction of the skin characterized by the frequent and continuous appearance of short-lived wheal reactions (1). IgG autoantibodies (autoAbs) directed against the α chain of the high-affinity IgE receptor (FceRIα) occur frequently in CU and may be of pathogenetic significance (2–5). The methodology used for the detection of these autoAbs includes histamine release (HR) assays from basophils (2), skin testing with autologous serum (6), and Western blotting/immunoprecipitation with purified serum IgG (3). While HR and skin tests detect biologically relevant mast cell/basophil–activating serum factors, they provide little, if any, information about the molecular configuration of these moieties, and the need for biologic material as assay substrate renders the standardization of these tests difficult. Western blotting and immunoprecipitation with purified serum IgG have been used successfully to identify FcεRIα-specific IgG autoAbs (3). These tedious procedures are hardly suited for screening purposes and of only limited value for determination of autoAb titers. To overcome these limitations, we attempted to establish a reliable ELISA-based assay for qualitative and quantitative analysis of IgG anti-FcεRIα autoAbs from non-fractionated serum samples. The availability of this test system allowed us to screen sera from large patient cohorts for the presence of IgG anti-FcεRIα autoAbs and, consequently, to determine the disease association of this autoreactivity and glean information concerning the molecular events operative in autoAb-induced activation of FcεRI-bearing effector cells.

Methods

Patients and controls. 281 patients with CU, defined as recurrent wheals lasting < 24 h and occurring at least twice a week for over 2 nts, were recruited (1,7). Patients with signs of urtiacal vasculitis or physical urticaria were excluded. In addition, sera from patients with the established diagnosis of atopic dermatitis (AD, n = 32), SLE (n = 15), psoriasis (PS, n = 30), bullous pemphigoid (BP, n = 22), dermatomyositis (DM, n = 45), and pemphigus vulgaris (PV, n = 28) were collected. Sera from 41 healthy individuals served as controls. All sera were stored at −20°C until investigation.

Human recombinant soluble FcεRIα (rsFcεRIα). The baculovirus-mediated expression and immunoaffinity purification of rsFcεRIα has been described previously (3). Biotin-labeled rsFcεRIα (rsFcεRIαbiot) was produced using NHS-LC-Biotin II (Pierce Chemical Co., Rockford, IL) according to the manufacturer’s guidelines.

Establishment of an anti-FcεRIα autoAb ELISA. Depending on the experimental conditions chosen, 1:15, 1:100, or 1:400 serum dilutions were reacted with mAbs directed against the CH3 domain of IgE (mAb BSW17 [8]) for 3 h at room temperature (RT). Aliquots of individual samples were incubated overnight at 4°C in the absence or

1. Abbreviations used in this paper: Ab, antibody; AD, atopic dermatitis; BP, bullous pemphigoid; CR, complement receptor; CU, chronic urticaria; DM, dermatomyositis; FcεRI, high-affinity receptor for IgE; HR, histamine release; PS, psoriasis; PV, pemphigus vulgaris; rRhPV L1, recombinant rhesus papilloma virus L1 protein; rsFcεRIα, recombinant soluble α chain of FcεRI; RT, room temperature; scOD, specific dilution–corrected optical density; Th, T helper.

presence of nonbiotinylated rsFcRIα or baculovirus-expressed human papilloma virus L1 protein (rRhPVL1, kindly provided by Dr. R. Kirnbauer [9]), each at a final concentration of 0.05–40 ng/ml. Thereafter, all samples were reacted with rsFcRIαbound (2 nM) for 3 h at 37°C. 100 μl aliquots of these reaction mixtures were transferred to streptavidin (Bio-Rad Laboratories, Hercules, CA)-coupled ELISA plates (Costar Corp., Cambridge, MA) and incubated for 1 h at RT. After several rounds of washing, plates were reacted with peroxidase-coupled goat F(ab’)2 anti-human IgG (1:10,000), F(ab’2) anti-human IgM (1:10,000), or F(ab’)2 anti-human IgE Abs (1:2,000; all from Sigma Chemical Co., St. Louis, MO) for 1 h at RT. Plate-bound enzyme was visualized using 2,2′-azino-bis(3-ethylbenzthiazoline-sulfonic acid) (ABTS; Sigma Chemical Co.) as a substrate. The reaction was stopped when the extinction of the ELISA wells exposed to an anti-FcRIα autoAb-containing control serum and, subsequently, to enzyme-labeled anti-human IgG reached an OD of 1.0 at a wavelength of 405 nm. The ODs of individual samples were multiplied by the serum dilution factor (corrected OD, cOD). The specific cOD (scOD) of individual samples was calculated by subtracting the cOD in the presence of competing nonbiotinylated rsFcRIα from the cOD in its absence. The mean scOD of healthy individual’s sera plus 2.5× SEM was calculated as the threshold level for anti-FcRIα autoAb reactivity.

The complement-binding capacity of rsFcRIα bound autoAbs was determined by using the same ELISA procedure with the modification that rabbit anti-human Clq, C3b, C3d, or C5a (all diluted 1:2,500; all from Serotec Ltd., Blackhorn, UK) followed by peroxidase-coupled goat F(ab’)2 anti-rabbit IgG (1:10,000; Amersham International, Buckinghamshire, UK) was used instead of the peroxidase-labeled F(ab’)2 anti-human IgG as the detection reagent.

SDS-PAGE and immunoblotting. The immunoblotting technique used for the detection of anti-FcRIα autoAbs in serum IgG isolates has been described previously (3). Briefly, rsFcRIα was electrophoresed on 10–13% SDS gels and blotted onto nitrocellulose membranes (Bio-Rad Laboratories) which were then exposed to 5% dry milk/0.05% Tween 20 (Sigma Chemical Co.)/PBS for at least 6 h. For the detection of FcRIα-reactive serum Abs, membranes were reacted with 1:10 diluted, mAb BSW17–prereacted serum specimens, and FcRIα-bound IgG was detected with rabbit anti-human IgG (1:50,000; Jackson ImmunoResearch Laboratories, Inc., Richmond, CA). For analysis of IgG subtype composition of anti-FcRIα reactive autoAbs, serum-exposed membranes were reacted with mAbs against human IgG1, IgG2, IgG3, or IgG4 (20 μg/ml, clones G17-1, G18-21, G18-3, and JDC-14; all from Pharmingen, San Diego, CA) followed by a goat anti-mouse horseradish peroxidase conjugate (1:1,000; Bio-Rad Laboratories) and ECL developing solution (Amersham International).

HR. HR assays were performed with basophil-enriched peripheral blood cells from three unrelated healthy donors as described previously (3). After dextran sedimentation, basophil-enriched cells were incubated for 40 min at 37°C in IL-3 (50 pg/ml; Endogen, Inc., Cambridge, MA)-supplemented buffer containing 1:10 dilutions of either native or heat-decomplemented (3 h, 56°C) patients’ sera or 0.5–1.0 mg/ml protein G (Pierce Chemical Co.)-eluted serum IgG. Before use in the HR assay, all sera/IgG fractions were exposed to 0.5–1.0 mg/ml protein G (Pierce Chemical Co.)–eluted serum IgG. For analysis of IgG subtype composition of anti-FcRIα reactive autoAbs, serum/IgG fractions were subjected to the same binding-inhibition protocol (Fig. 2). To test whether serum biotin and/or FcRIα-nonreactive serum IgG can influence ELISA results, we exposed streptavidin-coated plates overnight to various concentrations of an anti-FcRIα autoAb+ serum pool before the assay procedure, or titrated FcRIα-nonreactive sera to a fixed concentration of autoAb+ or autoAb− sera. As demonstrated in Fig. 2, neither the presence of serum biotin (Fig. 2 A) nor the serum IgG concentration (Fig. 2 B) affects the detectability of anti-FcRIα–reactive IgG autoAbs. To better analyze the specificity of the assay, anti-FcRIα–reactive sera were exposed to various concentrations of nonbiotinylated rsFcRIα and, for control purposes, rRhPVL1 before subjecting them to the ELISA procedure. Whereas the irrelevant protein rRhPVL1 did not affect the binding of anti-FcRIα–reactive IgG (Fig. 2 C), preincubation with rsFcRIα resulted in a dose-dependent decrease in the amount of plate-bound anti-FcRIα autoAbs, with a half-maximal inhibition at a molar ratio of nonbiotinylated competitor to biotinylated ligand of 0.5 (Fig. 2, C and D). No change in the anti-IgG signal occurred when Western blot autoAb+ control sera were subjected to the same binding-inhibition protocol (Fig. 2, C and D). As a consequence, IgG anti-FcRIα serum reactivity can be expressed as the absolute OD measured in ELISA or, more specifically, by the reduction in OD achieved by prereaction of diluted test sera with defined concentrations of nonbiotinylated rsFcRIα competitor protein (scOD). In the following experiments, we used a competitor:ligand ratio of 1.0 and calculated the scOD as the quantitative measure for IgG anti-FcRIα immunoreactivity. The threshold scOD level for

The modulation of serum-induced HR by either basophil pretreatment with complement receptor–inhibitory peptides or by heat decomposition of sera was expressed as percent inhibition of the HR induced by native serum on nonmodified basophils.

Statistical analysis. Statistical significance was determined using the Wilcoxon signed rank test, and a P value of < 0.05 was considered significant. Correlation coefficients were calculated using Cricket-Graph software.

Results

ELISA-based detection of IgG anti-FcRIα autoAbs. We aimed at designing an assay system that allows the detection of serum molecules with affinity for the extracellular portion of FcRIα. The system developed consists of two subsequent reaction steps: (a) a ligand (i.e., serum antibody)–target (i.e., biotinylated rsFcRIα) interaction in liquid phase and (b) the immobilization of ligand–target complexes onto streptavidin-coated matrices. The latter step allows the solid phase enzyme-based immunodetection of FcRIα-bound serum components. Substantial IgG binding to rsFcRIα was seen in the case of certain CU sera but in none of the AD specimens tested (Fig. 1 A, a representative experiment). As expected, we observed IgE binding to rsFcRIα in IgE-containing CU and AD sera (Fig. 1 B, a representative experiment). Since IgE can inhibit autoAb binding to FcRIα presumably by masking relevant epitopes on this molecule (3), and serum IgE–IgG complexes formed in vivo (11, 12) may produce false positive results in the rsFcRIα binding and anti-IgG detection system, we tried to eliminate serum IgE interference by exposing sera to anti-IgE mAbs recognizing the FcRIα-binding CH3 domain of IgE. Indeed, anti-IgE treatment abolished the serum IgE–derived signals (Fig. 1 B) but, importantly, did not diminish CU-IgG binding to rsFcRIα (Fig. 1 A). To test whether serum biotin and/or FcRIα-nonreactive serum IgG can influence ELISA results, we exposed streptavidin-coated plates overnight to various concentrations of an anti-FcRIα autoAb+ serum pool before the assay procedure, or titrated FcRIα-nonreactive sera to a fixed concentration of autoAb+ or autoAb− sera. As demonstrated in Fig. 2, neither the presence of serum biotin (Fig. 2 A) nor the serum IgG concentration (Fig. 2 B) affects the detectability of anti-FcRIα–reactive IgG autoAbs. To better analyze the specificity of the assay, anti-FcRIα-reactive sera were exposed to various concentrations of nonbiotinylated rsFcRIα and, for control purposes, rRhPVL1 before subjecting them to the ELISA procedure. Whereas the irrelevant protein rRhPVL1 did not affect the binding of anti-FcRIα–reactive IgG (Fig. 2 C), preincubation with rsFcRIα resulted in a dose-dependent decrease in the amount of plate-bound anti-FcRIα autoAbs, with a half-maximal inhibition at a molar ratio of nonbiotinylated competitor to biotinylated ligand of ~ 0.5 (Fig. 2, C and D). No change in the anti-IgG signal occurred when Western blot autoAb+ control sera were subjected to the same binding-inhibition protocol (Fig. 2, C and D). As a consequence, IgG anti-FcRIα serum reactivity can be expressed as the absolute OD measured in ELISA or, more specifically, by the reduction in OD achieved by prereaction of diluted test sera with defined concentrations of nonbiotinylated rsFcRIα competitor protein (scOD). In the following experiments, we used a competitor:ligand ratio of 1.0 and calculated the scOD as the quantitative measure for IgG anti-FcRIα immunoreactivity. The threshold scOD level for
IgG anti-FcRια reactivity was estimated as mean scOD plus 2.5× SEM produced by sera from 41 healthy individuals (Fig. 3). Based on this calculation, a given serum specimen contains anti-FcRια autoAbs if scOD > 39. To control the validity of this approach, we performed comparative Western blot and ELISA analyses. We found that immunoblot-reactive sera exhibited pronounced ELISA reactivity in all five cases tested (mean scOD±SEM: 120±76), and all four immunoblot nonreactive samples yielded an ELISA reactivity below the threshold level (mean scOD±SEM: 25±6). Due to high background staining, certain sera (n = 3) could not be judged either autoAb+ or autoAb- by Western blot. By ELISA, the same sera were found to contain either low anti-FcRια autoAb levels or were autoAb- (mean scOD±SEM: 33±52). These findings indicate that the results achieved by the ELISA-based detection system not only correlate with Western blot analysis but may be even more reliable when a given serum contains low autoAb titers.

**Figure 1.** mAbs directed against CHε3 (IgE heavy chain) inhibit serum IgE but not IgG binding to rsFcyRIa. mAb BSW17–pretreated (black bars) or non-treated (white bars) sera (diluted 1:15) from an AD and two chronic urticaria patients (CU 1 and CU 2) were exposed to biotinylated rsFcyRIa, and the ELISA procedure was carried out as described in Methods. OD of rsFcyRIa-bound anti-IgG (A) and anti-IgE (B) reactivity is given on the y axis.

**Figure 2.** Specificity and reliability of rs-FcyRIa-based ELISA. (A) Serum biotin does not interfere with detection of IgG anti-FcRια autoAbs. Streptavidin-coated ELISA plates were incubated overnight at the indicated concentrations with a pool of anti-FcRια-nonreactive sera. After three washes, ELISA was performed with one anti-FcRια-nonreactive (○) and two anti-FcRια-reactive (□ and ●) sera (all diluted 1:400). The OD produced by these samples is depicted as a function of the serum concentration added to the plates before the assay. (B) Serum components of FcyRIα-nonreactive sera do not interfere with detectability of IgG anti-FcRια autoAbs. Anti-FcRια-reactive (□) and -nonreactive (○) specimens (all sera diluted 1:400) were mixed with an FcRια-nonreactive serum pool at the final concentrations indicated and then subjected to ELISA. The same sera as in A were used. (C) Competitive cold inhibition of IgG anti-FcRια autoAb binding to biotinylated rsFcyRIa. Anti-FcRια-reactive (squares) and -nonreactive (circles) sera were reacted with the indicated concentration of nonbiotinylated rsFcyRIa (filled symbols) or rRhPVL1 (open symbols) before the assay procedure. (D) Effect of the molar competitor (nonlabeled rsFcyRIa) to ligand (biotinylated rsFcyRIa) ratio on the detectability of anti-FcRια autoAbs. The mean competitor-induced inhibition (±SEM) of anti-IgG immunoreactivity (x axis) is depicted as the function of the competitor to ligand ratio used (y axis). Filled squares and open circles, Mean inhibition values obtained with anti-FcRια-reactive (n = 2) and -nonreactive (n = 3) serum specimens, respectively.
Prevalence of anti-FcεRIα autoAbs in various (auto)immune-mediated diseases. We next evaluated the prevalence of IgG anti-FcεRIα autoAbs in sera from patients suffering from CU or AD. Results obtained confirmed and extended those of our previous Western blot studies (3): 38% of the CU patients (106/281) exhibited anti-FcεRIα reactivity, whereas none of the 32 AD serum specimens contained anti-FcεRIα autoAbs (Fig. 3). Furthermore, 30 sera from patients with PS were uniformly devoid of anti-FcεRIα autoAbs (Fig. 3). These data suggest that cutaneous inflammation per se does not suffice for autoimmune sensitization to FcεRIα. However, the possibility existed that tissue-specific or systemic autoimmunity might lower the threshold of immunocompetent cells to recognize FcεRIα. To test this assumption, we screened sera from patients with cutaneous autoimmune manifestations only (BP or PV) or with skin involvement in the context of a systemic autoimmune disease (SLE or DM). Interestingly, we identified FcεRIα autoAb-containing sera in all of these patient groups regardless of whether the disease entity was of systemic or skin-restricted nature (Fig. 3). The specificity of the ELISA results in these patient groups was confirmed by our finding that sera from DM (n = 9), BP (n = 2), and PV (n = 2) patients, which were unequivocally autoAb+ by ELISA, always displayed pronounced IgG reactivity against Western-blotted rsFcεRIα. It is noteworthy that the anti-FcεRIα–sensitization rates and autoAb titers found in patients with these autoimmune diseases are roughly equal to those of CU patients.

IgG anti-FcεRIα–reactive CU sera can release histamine from basophils. We next tested whether diluted sera from the various patient groups can activate basophils from healthy donors. As demonstrated in Fig. 4 A, IgG autoAb–containing CU sera exhibited pronounced histamine-releasing activity. CU sera that lacked IgG anti-FcεRIα autoAbs had significantly lower histamine-releasing activity than those containing autoAbs (P < 0.001) and, in this respect, did not differ from sera of healthy individuals. The percentage of sera with basophil-activating properties (i.e., samples that induced an HR > 15% of the positive control) was 66% in the autoAb+ and 17% in the autoAb− CU subgroups. Interestingly, the autoAb titers in the histamine-releasing and the nonreleasing autoAb+ CU sera were not significantly different (P > 0.05). Irrespective of autoAb status, sera from non-CU autoimmune patient groups
did not contain more histamine-releasing activity than sera from healthy controls (Fig. 4 A). It is unlikely that differences in autoAb concentrations are responsible for the observed phenomenon, since CU sera and sera from the other disease entities contained similar amounts of IgG autoAbs (Fig. 4 B). To test the possibility that IgM anti-FcRIα autoAbs occur in the IgG autoAb+ CU sera and may contribute critically to the basophil-activating properties of these specimens, we modified our ELISA protocol by substituting the anti-IgG for an anti-IgM immunodetection step. Comparatively weak IgM anti-FcRIα reactivity was detected in CU sera as well as sera from the other groups investigated, and was not linked to IgG autoAb status (data not shown). Thus, it appears that IgG rather than IgM anti-FcRIα autoAbs are responsible for basophil activation. This finding suggests further that these IgG autoAbs in CU exhibit structural and/or functional properties that are not shared by the autoAbs occurring in the other diseases.

Disease-restricted IgG subtypes of anti-FcRIα autoAbs. Analysis of the IgG subtypes of anti-FcRIα autoAbs in various disease groups revealed striking differences. In CU sera, we found a predominance of IgG1 (55%; n = 22) and IgG3 autoAbs (77%; Table I). AutoAbs of either IgG1 or IgG3 subtype were observed in 91% of these serum specimens. IgG2 occurred in only 3 of 22 samples (14%) and FcRIα-specific IgG4 was evident in 3 of 22 specimens (14%). In a single CU patient, we detected IgG4 but no IgG1 or IgG3 autoAbs. In contrast, IgG2 or IgG4 autoAbs accounted for the anti-FcRIα reactivity in the majority of patients suffering from DM (89%, n = 9; Table I), PV (100%, n = 2; data not shown), or BP (100%, n = 2; data not shown). Seven DM serum specimens contained IgG2 (78%), and five (56%) displayed IgG4 anti-FcRIα reactivity, whereas FcRIα-specific IgG1 and IgG3 were found in only two (22%) and three (33%) samples, respectively. A single DM patient displayed IgG3 but no IgG2 or IgG4 autoAbs. Taken together, the predominance of IgG1 and IgG3 autoAbs in histamine-releasing CU sera and the low prevalence of this immunoreactivity in sera from the other disease groups suggests that IgG subtype–dependent functions may be of pathogenetic relevance for the occurrence of autoimmune mast cell/basophil activation.

Anti-FcRIα autoAbs from CU sera exhibit complement-activating properties in vitro. To analyze the complement-activating properties of anti-FcRIα autoAbs after ligand binding, we modified the ELISA protocol by exchanging the anti-IgG detection step for an incubation with enzyme-labeled Abs specific for various complement components. In this assay, we detected substantial quantities of complement factor C3d–binding autoAbs in the anti-FcRIα–reactive CU but not DM, SLE, BP, or PV sera (Fig. 5 A). A short period of heat treatment, which leads to serum decomplementation but, reportedly, does not affect the autoAb–target interaction (3), abolished the occurrence of autoAb–associated anti-C3d immunoreactivity (Fig. 5 A). In none of the disease groups could autoAb-bound C1q, C3b, or C5a be detected (data not shown). This result is not surprising, as these moieties, unlike C3d, undergo rapid degradation unless stabilized artificially (13). To test the possibility that the complement-binding activity of anti-FcRIα autoAbs may be of importance for their basophil-activation properties, 11 anti-FcRIα CU serum samples were selected on the basis of their histamine-releasing activity (HR > 15%) and subjected to HR assays in both native and heat-decomplemented form. Decomplementation resulted in a substantial reduction of the HR induced by 9 of 11 samples, which correlated well in magnitude (r² = 0.49, P < 0.05) with the scOD values obtained in the anti-C3d ELISA (Fig. 5 B). In three further experiments, a total of 21 anti-FcRIα autoAb–containing CU serum samples were analyzed for the impact of basophil complement receptor (CR) triggering on the autoAb–elicited HR. Similar to the results shown in Fig. 5 B, a substan-

<table>
<thead>
<tr>
<th>Subtype</th>
<th>CU</th>
<th>DM</th>
</tr>
</thead>
<tbody>
<tr>
<td>n = 22</td>
<td>n = 9</td>
<td></td>
</tr>
<tr>
<td>IgG1</td>
<td>55% (12/22)</td>
<td>22% (2/9)</td>
</tr>
<tr>
<td>IgG2</td>
<td>14% (3/22)</td>
<td>78% (7/9)</td>
</tr>
<tr>
<td>IgG3</td>
<td>77% (17/22)</td>
<td>33% (3/9)</td>
</tr>
<tr>
<td>IgG4</td>
<td>14% (3/22)</td>
<td>56% (5/9)</td>
</tr>
<tr>
<td>IgG1 or IgG3</td>
<td>91% (20/22)</td>
<td>44% (4/9)</td>
</tr>
<tr>
<td>IgG2 or IgG4</td>
<td>27% (6/22)</td>
<td>89% (8/9)</td>
</tr>
<tr>
<td>IgG1/3 but not IgG2/4</td>
<td>73% (16/22)</td>
<td>11% (1/9)</td>
</tr>
<tr>
<td>IgG2/4 but not IgG1/3</td>
<td>5% (1/22)</td>
<td>56% (5/9)</td>
</tr>
</tbody>
</table>
tion of rsFcRIα autoAbs is linked to their complement-fixing properties. (A) Selectively, anti-FcRIα autoAbs from CU patients fix substantial amounts of the complement factor C3d upon target binding. Native (black bars) or heat-decomplemented (3 h, 56°C; white bars) serum specimens were analyzed by ELISA for autoAb-mediated C3d binding, and data were expressed as mean scOD ± SEM for each group investigated. (B) Correlation of C3d binding and decomplementation-sensitive HR by IgG anti-FcRIα autoAbs. 11 histamine-releasing (HR > 15%) autoAb+ CU sera (■) were incubated in heat-decomplemented and native form with basophils. Results obtained with individual samples are given as decomplementation-induced reduction in HR relative to release induced by native serum versus C3d-binding capacity of serum-derived autoAbs. (C) Decomplementation of CU sera as well as C5aR blockade on basophils result in substantial inhibition of serum-induced HR. 21 decomplemented and native sera (HR > 10%) were incubated with basophils either nonmodified or (pre)exposed to C5aR-blocking peptides. Results obtained with individual sera (●) are given as decomplementation- and C5aR blockade–sensitive HR. Inhibition values < 1 were set to the 1% level on the logarithmic scale.

Figure 5. The histamine-releasing activity of IgG anti-FcRIα autoAbs is linked to their complement-fixing properties. (A) Selectively, anti-FcRIα autoAbs from CU patients fix substantial amounts of the complement factor C3d upon target binding. Native (black bars) or heat-decomplemented (3 h, 56°C; white bars) serum specimens were analyzed by ELISA for autoAb-mediated C3d binding, and data were expressed as mean scOD ± SEM for each group investigated. (B) Correlation of C3d binding and decomplementation-sensitive HR by IgG anti-FcRIα autoAbs. 11 histamine-releasing (HR > 15%) autoAb+ CU sera (■) were incubated in heat-decomplemented and native form with basophils. Results obtained with individual samples are given as decomplementation-induced reduction in HR relative to release induced by native serum versus C3d-binding capacity of serum-derived autoAbs. (C) Decomplementation of CU sera as well as C5aR blockade on basophils result in substantial inhibition of serum-induced HR. 21 decomplemented and native sera (HR > 10%) were incubated with basophils either nonmodified or (pre)exposed to C5aR-blocking peptides. Results obtained with individual sera (●) are given as decomplementation- and C5aR blockade–sensitive HR. Inhibition values < 1 were set to the 1% level on the logarithmic scale.

Inhibiting IgE-mediated allergic tissue inflammation in vitro and in vivo (17–19). To test whether rsFcRIα could be of similar benefit for the inhibition of autoAb-dependent effector cell activation, anti-FcRIα–reactive and -nonreactive CU as well as sera from healthy controls were exposed to rsFcRIα before basophil challenge. AutoAb+ CU sera were selected on the basis of their high (HR > 30%; HR+) and low or absent (HR < 15%; HR−) HR capacity. Preadsorption of diluted HR+ CU sera with 0.5 µg/ml rsFcRIα led to a substantial reduction in their basophil-activating capacity (P < 0.05; Fig. 6A). In striking contrast, the anti-autoAb+ CU sera, which had displayed only limited HR activity in the absence of rsFcRIα, induced robust basophil activation in its presence (Fig. 6A). This phenomenon appears to depend critically on IgG anti-FcRIα autoAbs, since the autoAb− CU as well as the autoAb+ sera from healthy controls were not able to mount a similar response. To address experimentally the mechanism(s) leading to the rsFcRIα/anti-FcRIα autoAb–induced response, we analyzed the rsFcRIα-dependent HR capacity of sera and IgG fractions from CU patients and controls. As exemplified in Fig. 6B, the occurrence of rsFcRIα–induced HR critically requires not only anti-FcRIα autoAbs but also non–IgG serum components, since IgG anti-FcRIα–reactive HR+ CU sera but not IgG fractions therefrom activated basophils in the presence of soluble FcRIα. As expected, the HR induced by an HR+ CU serum and its IgG fraction were reduced in the presence of rsFcRIα (Fig. 6B). To investigate whether the in vitro–formed rsFcRIα/anti-FcRIα autoAb complexes in HR+ sera may activate FcRI-bearing effector cells via CR triggering, basophils were exposed to HR+ autoAb+ (n = 4) and autoAb− (n = 1) CU sera in the presence or absence of inhibitory C5a peptides and/or rsFcRIα. As demonstrated in Fig. 6C, C5aR blockade abolishes rsFcRIα–induced HR, indicating that anti-FcRIα autoAbs upon binding to their recombinant target can initiate complement breakdown and subsequent
C5a-dependent basophil activation. In contrast, C5a-inhibitory peptides neither affected the HR capacity of autoAb+ CU sera (Fig. 6 C) nor reduced the magnitude of the HR induced by mouse mAbs directed against FcRIα (data not shown). In contrast to the substantial contribution of CR triggering for autoAb-mediated HR, a putative role of autoAb Fc part–FcγR interactions on basophils appears to be of minor relevance, as the functional blockade of the low affinity FcγR, FcγRII, by Fab fragments of the mAb IV-3 did not affect significantly the autoAb+ or autoAb–rsFcRIα complex–induced HR (data not shown).

Discussion

In this study, we demonstrate that IgG anti-FcRIα autoAbs occur not only in CU patients but can also be detected in sera of patients suffering from other systemic or skin-restricted autoimmune diseases. Anti-FcRIα autoAbs in CU but not in the other autoimmune-mediated disorders are of apparent functional relevance, as they can activate FcRI-bearing effector cells. An explanation for this discrepancy can be derived from the observation that the autoAb-induced pathogenetic events in CU patients can include complement activation and, thus, involve mechanisms other than mere ligation of FcRI.

FcRIα-specific IgG autoAbs with basophil-activating properties occur in a considerable proportion of CU patients (2, 3), and the reduction of serum IgG and, probably, autoAb levels can ameliorate disease activity temporarily in these individuals (20). These findings emphasize the need for a reliable and fast screening system that allows identification of autoAb-bearing hosts and monitoring of autoAb serum levels during the course of the disease. Here we present an ELISA system that uses the recombinant extracellular portion of FcRIα as the reaction target for serum autoAbs. Unlike a previously described biochemical test (3), the new protocol circumvents the necessity of serum IgE depletion by the introduction of an incubation step with anti–human CH3 (IgE heavy chain) mAbs that prevent interference of IgE with the test substrate rsFcRIα. Furthermore, detection of autoAbs recognizing conformational epitopes on FcRIα is favored by the use of native target protein rather than SDS-denatured material in the biochemical analysis. As opposed to the commonly used functional assays, i.e., basophil HR and skin testing with autologous serum (2, 6), the ELISA-based assay allows identification and quantification of anti-FcRIα autoAbs irrespective of their in vitro basophil/mast cell–activating properties. This seems of particular importance, since the occurrence of autoAb-induced HR in vitro does not always correlate with that of serum IgG anti-FcRIα autoreactivity (reference 3, and this study). As a further advantage, the liquid phase autoAb binding and detection system offers the possibility not only of searching for the presence of anti-FcRIα autoAbs but also of analyzing their isotype(s) and some of their functional (e.g., complement-fixing) properties.

Large scale screening of sera revealed the presence of IgG anti-FcRIα autoAbs not only in 38% of CU patients but also in a proportion of sera from patients with organ-specific (BP [13%] and PV [39%]) or systemic autoimmune diseases (SLE [20%] and DM [36%]). Sera from healthy individuals as well as from patients with atopic or psoriatic skin inflammation were devoid of IgG anti-FcRIα immunoreactivity. The occurrence of anti-FcRIα autoAbs seems to parallel the distribution pattern of FcyR-specific autoAbs detected in sera from autoimmune (e.g., SLE or RA) patients but not in sera from healthy individuals (21). Importantly, most of these FcyR-reactive autoAbs are of the IgM isotype, indicating low substrate specificity and affinity as well as absence of FcyR-specific T helper (Th) cells. Concerning anti-FcRIα autoAbs, antigen-specific IgM appears to be of minor importance, since this immunoreactivity (a) was found only in low titers in the
various patient groups, (b) did not correlate in magnitude with the titer of IgG autoAbs of the same specificity, and (c) could be detected even in some of the sera from healthy controls (data not shown). Thus, it is conceivable that in CU as well as in other autoimmune diseases, affinity-matured IgG autoAbs account for most of the observed humoral anti-FceRIα reactivity. Although FceRIα-specific T cells capable of providing IgG isotype switch and maturation signals for B cells have not yet been isolated, the occurrence of IgG1 and IgG3 autoAbs in CU as opposed to IgG2 and IgG4 autoAbs in the other autoimmune diseases suggests that FceRI-specific T cells exist in vivo, and that these cells display a disease-specific polarized secretory potential. In particular, isotype switching to IgG4 in humans (and to IgG1 in mice) depends on the presence of IL-4–producing Th2 cells, whereas the production of the murine homologues of the human complement-binding IgG1 and IgG3 isoforms (22) is IFN-γ– and, thus, Th1 cell–dependent (23).

In this study, we found a high prevalence of complement-fixing and basophil-activating anti-FceRIα autoAbs in CU, whereas apparently nonfunctional autoAbs without complement-activating properties occur preferentially in non-CU autoimmune diseases. Our contention that complement activation by autoAbs in CU is of functional significance is supported by the finding that decomplementation of most autoAb-containing sera reduces significantly their HR capacity (Fig. 5, B and C), and that the C3d-binding activity of anti-FceRIα autoAbs correlates with the magnitude of the decomplementation-sensitive portion of the serum-induced HR (Fig. 5 B). The complement receptor most likely involved is C5aR, since CU-IgG can reduce basophil anti-C5aR immunoreactivity in a C5-dependent manner (data not shown), and the blockade of C5aR (Fig. 5 C) but not of C3aR (data not shown) results in a substantial inhibition of the HR induced by autoAb+ CU sera. An augmentative functional interplay of signal transduction via the tyrosine kinase–activating FceRI and the G protein–coupling C5aR (16, 24–26) is suggested by our preliminary observations that the exposure of basophils to anti-FceRIα–reactive CU-IgG fractions can lower the cells’ threshold to respond to recombinant C5a (data not shown). The further observations that a subset of anti-FceRIα autoAb+ sera activated basophils in an entirely complement/C5aR-independent manner, and that many sera displayed a complement/C5aR-independent component of HR activity (Fig. 5, B and C), suggest that the relative contribution of autoAb-induced FceRI cross-linking and CR triggering varies among individual specimens.

A surprising observation in this study is that certain anti-FceRIα autoAb–containing CU sera failed to trigger basophil degranulation. Low autoAb levels in these sera are apparently not responsible for the lack of effector cell stimulation, since, by ELISA, IgG anti-FceRIα reactivity was of comparable magnitude in histamine-releasing and nonreleasing autoAb+ CU serum samples. A likely explanation is that autoAbs in the latter sera recognize preferentially epitopes on soluble FceRIα that are hidden on the membrane-bound receptor form expressed on basophils from healthy donors. This argument gains support from our finding that the HR–anti-FceRIα autoAbs can upon complexation with their soluble ligand convert into stimulatory agents which release histamine from basophils in a complement/C5aR-dependent manner (Fig. 6). But how can it be that such autoAbs are pathogenic in vivo? A particularly tempting speculation is that certain cell types (e.g., mast cells, antigen-presenting cells of the skin) not only express cell surface–bound FceRIα, but can also release the α chain as a soluble molecule. This appears not too unlikely, since many Fc receptor types, i.e., FcyRII/CD32, FcyRIII/CD16, and FceRI/CD23, have been shown to exist in soluble forms (27–30). Thus, in certain cases of CU, tissue-bound soluble FceRIα may allow the localized formation of anti-FceRIα autoAb–containing immune complexes capable of complement activation and C5a-dependent mast cell stimulation.

In summary, our observations ascribe to the complement system an augmentative and perhaps, in certain cases, critical pathogenetic role in autoimmune-mediated CU. This concept gains support from the in vivo observations that the treatment of CU patients with pharmacological inhibitors of complement activation can reduce disease activity (31), and that, unlike in normal skin, mast cells within lesional skin of CU patients lack anti-C5aR immunoreactivity, possibly due to C5a-mediated occupation, downregulation, and/or shedding of this receptor (32). If the proposed pathophysiologic scenario is of relevance in vivo, the skin-restricted distribution of symptoms in CU could be explained by the fact that mast cells of the skin but not of either the lung or intestinal mucosa express C5aR (33, 34).

The treatment modalities currently used for CU serve mainly to ameliorate symptoms rather than to cure, and, unfortunately, only incomplete remission frequently results. The rsFceRIα-based extracorporal adsorption of serum autoAbs and the pharmacologic modulation of their target binding properties are strategies certainly worth pursuing. Systemic administration of rsFceRIα, which may be of benefit in IgE-mediated allergic tissue inflammation, appears to be a treatment modality less well-suited for autoimmune CU, as this compound may exaggerate the disease activity in a complement-dependent manner and, thus, result in anaphylaxis and/or immune complex disease. A new attractive prospect would be to interfere in a concerted fashion with autoAb binding to IgE receptors and anti-FceRIα autoAb–induced complement activation, thus blocking the initiation of the pathological cascade that results in this distressing affliction.

Acknowledgments

We wish to thank Dr. Sibylle Wichlas and Bärbel Reininger for helpful technical assistance, and Laura A. Stingl for critical reading of the manuscript.

This work was supported by Novartis Ltd., Basel, Switzerland.

References


